Big Pharma's Strategy Shifts After the ADC Frenzy
Capital Focuses on Validated Oncology Assets and Differentiated Data
Securing Late-Stage Value Remains a Challenge for Korean Biotech

The era of "ADC FOMO"—when, just two to three years ago, companies raced to acquire even unproven antibody-drug conjugate (ADC) candidates in a competitive frenzy—has come to an end. Now, capital is flowing into "validated late-stage assets." Major pharmaceutical companies are paying overwhelming premiums for late-stage oncology drugs that can generate immediate revenue, or are boldly betting on next-generation technologies that have demonstrated differentiated data for targets previously considered difficult to address with existing drugs.


In the past month alone, global big pharma investments in oncology drug assets have exceeded 20 trillion won. As of early June, the total value of global pharmaceutical and biotech mergers and acquisitions (M&A) in the first half of this year reached $106 billion (about 160 trillion won), marking the most active period since the peak in 2019, before the COVID-19 pandemic.


Leading the list of major deals is GlaxoSmithKline’s (GSK) $10.6 billion (about 14 trillion won) acquisition of NewValent. This is the largest acquisition GSK has undertaken in nearly a decade, executed at a 40% premium to NewValent’s closing price just before the announcement. Through this deal, GSK gains two lung cancer drugs already under review by the U.S. Food and Drug Administration (FDA). Around the same time, Johnson & Johnson (J&J) acquired Firefly Bio, a company with a technology platform that selectively degrades the protein KRAS, which is involved in cancer cell growth signals, for $1 billion (about 1.5 trillion won). Because KRAS has long been considered a difficult target, the technology itself for developing new drugs aimed at this protein is highly valued. Roche has also agreed to invest up to $3 billion (about 4 trillion won) in a co-development partnership with Nyliix, which has technology for degrading BTK, a protein that is a key target in blood cancer treatment.


The reason big pharma is willing to pay high premiums for these "validated assets" lies in the looming challenge known as the patent cliff. The blockbuster products that have supported the cash flow of major pharma companies will see their patents begin to expire one after another in the late 2020s. As the revenue holes open on predetermined dates and there is not enough time to develop new drugs from scratch, the fastest solution is to acquire assets with validated targets and near-term revenue potential. Such assets are rare and thus command even higher prices. The 40% premium paid for NewValent is seen not as market overheating, but as the price of "asset scarcity."

[Bio Talk] 10 Trillion Won Poured into 'Late-Stage Premiums'... Growing Dilemma for Korean Biotech View original image

The challenge for the Korean biotech sector is that it is structurally difficult to capture this "late-stage premium." The prevailing business model for domestic biotech companies is to secure development funds by out-licensing technologies at an early clinical stage, rather than carrying assets through to late clinical phases themselves. While this mitigates development risk, it also makes it structurally difficult to secure negotiating power for assets in the late phases, when clinical data accumulates and the probability of approval rises sharply, and asset value increases dramatically.


Alteogen is a representative example. Previously, Alteogen out-licensed its platform technology that changes the delivery method of antibody drugs to Merck (MSD). The subcutaneous injection formulation of Keytruda using this technology was approved last year. Keytruda is a blockbuster drug that generates approximately 42 trillion won in annual sales, and the switch to a subcutaneous formulation is expected to open up new market value. However, according to Merck’s disclosures, Alteogen’s royalty is set at about 2% of net sales. While out-licensing reduces development risk, it also significantly limits the rights to the increased product value that comes with approval and commercialization.


As "late-stage asset premiums" grow, the criteria for evaluating new technology transfer markets are also changing. Investors are now asking not "How much did the company sell the asset for?" but "How far did the company carry the asset itself?" In the past, multi-trillion-won contract figures supported the growth narrative of Korean biotech firms, but now the key factors shaping corporate value are the clinical stage the asset has reached and the comparative data collected versus competitors. Industry insiders say that for Korean biotech to take the next leap, companies will need to prove their development capabilities by carrying assets through to higher-value stages, rather than settling for early technology transfer.



[Bio Talk] 10 Trillion Won Poured into 'Late-Stage Premiums'... Growing Dilemma for Korean Biotech View original image


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing